Arcellx, Inc. announced the closing of a Collaboration and License Agreement with Kite Pharma, Inc. and the sale of 3,478,261 shares of common stock to Gilead Sciences, Inc. for $100 million.
AI Assistant
ARCELLX INC
2023
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.